News - Page 66 - Psychedelic Alpha

Introducing The Psychedelic Practitioner, a new publication by Psychedelic Alpha.

Read more about the article Ehave Provides Progress Update on its HPPD Study with University of Melbourne

Ehave Provides Progress Update on its HPPD Study with University of Melbourne

Post published:February 2, 2023
Post category:Press Release

Read more about the article Reunion Neuroscience Schedules Fiscal Third Quarter 2023 Conference Call for Tuesday, February 14, 2023, at 8:30 A.M. ET

Reunion Neuroscience Schedules Fiscal Third Quarter 2023 Conference Call for Tuesday, February 14, 2023, at 8:30 A.M. ET

Post published:February 2, 2023
Post category:Press Release

Read more about the article Mindset Pharma Receives Another Allowance from USPTO for Patent Application Expanding Composition of Matter for Family 1 Psilocybin Analogs

Mindset Pharma Receives Another Allowance from USPTO for Patent Application Expanding Composition of Matter for Family 1 Psilocybin Analogs

Post published:February 2, 2023
Post category:Press Release

Read more about the article The Agenda for Economic Analyses of Psychedelic-assisted Therapy

The Agenda for Economic Analyses of Psychedelic-assisted Therapy

Post published:February 1, 2023
Post category:2022 Year in Review

Read more about the article A Perspective on Providers: Scaling PAT in a Time of Therapist Shortages

A Perspective on Providers: Scaling PAT in a Time of Therapist Shortages

Post published:February 1, 2023
Post category:2022 Year in Review

Read more about the article Making “Access” A Meaningful Part of Every Conversation about Psychedelic Therapy

Making “Access” A Meaningful Part of Every Conversation about Psychedelic Therapy

Post published:February 1, 2023
Post category:2022 Year in Review

Read more about the article Psychedelic Therapies: From Approvals to Access

Psychedelic Therapies: From Approvals to Access

Post published:February 1, 2023
Post category:2022 Year in Review

Read more about the article PharmaTher Holdings Submits FDA Meeting Package to Discuss Phase 3 Program and Fast Track Designation for KETARX™ (Ketamine) in Parkinson’s Disease

PharmaTher Holdings Submits FDA Meeting Package to Discuss Phase 3 Program and Fast Track Designation for KETARX™ (Ketamine) in Parkinson’s Disease

Post published:February 1, 2023
Post category:Press Release

Read more about the article Small Pharma Announces Update on Intellectual Property Portfolio with Two New Patents Approved for Issue

Small Pharma Announces Update on Intellectual Property Portfolio with Two New Patents Approved for Issue

Post published:February 1, 2023
Post category:Press Release

Read more about the article Numinus Receives Clinical Trial Application Approval from Health Canada for Experiential Psychedelic-Assisted Therapy Training using Psilocybe Cubensis Tea

Numinus Receives Clinical Trial Application Approval from Health Canada for Experiential Psychedelic-Assisted Therapy Training using Psilocybe Cubensis Tea

Post published:February 1, 2023
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.